Table 3 Clinical trials of chimeric antigen receptor T-cell therapy for B-cell lymphoma

NCT04169932

R/R B-cell lymphoma; NHL

CD20 CAR-T

Early phase I

20

(1, 2, 4, 8) × 10^6 cells/kg

NR

NCT03994913

R/R B-NHL

CD19 CAR-T

Phase I

Phase II

78

NR

NR

NCT04036019

B-cell lymphoma

CD20 CAR- T

Phase I

12

NR

NR

NCT04429438

B-cell lymphoma

4SCAR19 and 4SCAR20/22/70/PSMA/13/79b/GD2

Phase I

Phase II

11

NR

NR

NCT04381741

DLBCL

CD19 CAR-T plus PD1 monoclonal antibody

Phase I

24

(1, 2, 3)×

10^6 cells/kg plus 200 mg Tislelizumab every 3 weeks for 6 times

NR

NCT04260932

B-cell lymphoma

CD19/CD20 Dual- CAR-T

Phase I

12

Escalated dose of (1–6) × 10^6 cells/kg

NR

NCT03929107

B-cell lymphoma

IL-7 and chemokine ligand 19-expressing CD19-CAR-T cells

Phase II

80

NR

NR

NCT03854994

B-cell lymphoma; B-ALL

CD19 CAR-T Cells

Phase I

10

(1–5) × 10^6 cells/kg

NR

NCT04316624

DLBCL

C-CAR066

Phase I

10

Low: (1.0–3.0) × 10^6 cells/kg;

Medium: (3.0–6.0) × 10^6 cells/kg;

High: (6.0–9.0) × 10^6 cells/kg

NR

NCT04240808

NHL

UCD19 CAR T Cells

Phase I

20

NR

NR

NCT04539444

R/R NHL

CD19/22 CART

Phase II

20

3-day split-dose regimen at dose of (0.5–2) × 10^6 cells/kg

NR

NCT03881761

B-cell lymphoma

CD19/CD20 bispecific CAR-T

Phase I

50

(1–3) × 10^6 cells/kg

NR

NCT04486872

DLBCL

Autologous humanized CD19/CD20 bispecific CAR-T

Phase I

18

1.00 × 10^6 cells/kg, 3.00 × 10^6 cells/kg or 5.00 × 10^6 cells/kg

NR

NCT04257578

B-NHL; DLBCL; High grade B-cell lymphoma; PMBCL; tFL

Axicabtagene Ciloleucel

Phase I

Phase II

20

NR

NR

NCT03391726

B-cell lymphoma

CD19 CAR-T

Phase II

20

NR

NR

NCT04416984

B-cell lymphoma

ALLO-647

Phase I

Phase II

120

NR

NR

NCT03103971

B-ALL; DLBCL; PMBL; R/R B-NHL

CD19 CAR-T

Phase I

73

NR

NR

NCT03287817

DLBCL;

R/R DLBCL

AUTO3

Phase I

Phase II

171

(50–900) × 10^6 cells

NR

NCT04049513

B-NHL; DLBCL; PMBCL; tFL; FL; MCL

WZTL002–1

Phase I

12

Starting dose of 5 × 10^4 cells/kg

NR

NCT04432506

R/R DLBCL; R/R high grade B-cell lymphoma; R/R PMBCL; R/R tFL

Axicabtagene Ciloleucel

Phase I

20

NR

NR

NCT04532268

ALL; B-NHL

Humanized CD19 CAR-T cells

Early phase I

72

NR

NR

NCT03932955

Lymphoma

MC-19PD1 CAR-T cells

Phase I

15

NR

NR

NCT04191941

B-NHL; B-ALL; MM

Novel CAR-T

Phase I

9

NR

NR

NCT04007029

CLL; R/R DLBCL; FL; MCL; PMBCL; SLL

CAR-T

Phase I

24

NR

NR

NCT04163302

B-cell lymphoma

CD19-PD1-CAR-T Cell

Phase II

30

NR

NR

NCT04215016

R/R DLBCL Patients With Either CD19 or CD20 Positive

Autologous humanized CD19/CD20 bispecific CAR-T

Phase I

18

The first dose is 1.0 × 10^6 cells/kg, the second dose is 3.0 × 10^6 cells/kg and the third dose is 8.0 × 10^6/kg.

NR

NCT03664635

R/R B-NHL

MB-CART20.1

Phase I

Phase II

19

Safety dose level: 1 × 10^5 cells/kg;

Dose level 1: 1 × 10^6 cells/kg;

Dose level 2: 3 × 10^6 cells/kg.

NR

NCT04088890

B-ALL; B-NHL; DLBCL

CD22 CAR-T

Phase I

95

ALL: 3 × 10^5 cells/kg(±20%); B-NHL: 1 × 10^6 cells/kg, 3 × 10^6 cells/kg and 1 × 10^7 cells/kg

NR

NCT03366324

ALL;

B-cell lymphoma

Second generation CAR-T cells

Phase I

Phase II

20

NR

NR

NCT03277729

R/R B-NHL; CLL; R/R DLBCL; Recurrent FL; Recurrent MCL; Recurrent MZL

CAR-T

Phase I

Phase II

30

NR

NR

NCT04532281

ALL; NHL

CD19 CAR-T

Early phase I

120

NR

NR

NCT03398967

B-cell lymphoma

Dual specificity CD19 and CD20 or CD22 CAR-T Cells

Phase I

Phase II

80

NR

NR

NCT02965092

ALL;

B-cell lymphoma

Second generation CAR-T cells

Phase I

Phase II

80

(0.89–4.01) × 10^6 CAR-T cells/kg

Median overall survival (OS) was 16.1 months. The 6-month and 12-month OS rates were 69.727 and 64.028%.

NCT02963038

B-cell lymphoma

Autologous CD19- targeting CAR T

Phase I

Phase II

10

NR

NR

NCT03383952

B-cell lymphoma

ICAR19 CAR-T cells

Phase I

20

NR

NR

NCT04007978

B-cell lymphoma; ALL

Third generation CAR- T

Phase I

50

NR

NR

NCT04532203

ALL; NHL

CAR-T cells

Early phase I

72

NR

NR

NCT04603872

R/R MM; R/R ALL; R/R NHL

CD19/BCMA CAR T-cells

Early phase I

120

NR

NR

NCT03939026

R/R Large B-Cell Lymphoma; R/R FL

ALLO-647

Phase I

54

NR

NR

NCT04008251

ALL;

B-cell lymphoma

Second generation humanized CAR-T

Phase I

10

NR

NR

NCT03118180

Lymphoma

CD19 CAR-T

Phase I

Phase II

50

NR

NR

NCT02650414

B-cell lymphoma

CD22 CAR-T

Phase I

15

Subjects < 50 kg: (0.2–1) × 10^7 cells/kg

Subjects > 50 kg: (1–5) × 10^8 cells

NR

NCT04317885

B-NHL

CD19/CD20-directed CAR-T cells

Phase I

25

NR

NR

NCT03166878

B-cell lymphoma

UCART019

Phase I

Phase II

80

Day 0: 10% of total dose. Day 1: 30% of total dose if patient is stable. Day 2: 60% of total dose if patient is stable.

NR

NCT03720457

DLBCL; FL

CD19 CAR-T

Phase I

18

NR

NR

NCT03559439

B-cell lymphoma; B-ALL

CD19 CAR T

Phase I

9

Low: 1 × 10^5 cells/kg; Medium: 2 × 10^6 cells/kg; High: 6 × 10^6 cells/kg

NR

NCT04088864

B-cell lymphoma; ALL

Autologous CD22 CAR T

Phase I

52

R/R B-ALL: 1 × 10^6 cells/kg (±20%).

Lymphoma: 1 × 10^6 cells/kg (±20%).

NR

NCT03696784

B-cell lymphoma

iC9-CAR19 T cells

Phase I

30

(1–2) × 10^6 cells/kg

NR

NCT04204161

R/R ALL;

B-cell lymphoma

CAR-T19/CAR-T22

Phase I

30

The recommand dose: 1 × 10^5/kg-2.5 × 10^8/kg

NR

NCT03853616

ALL;

B-cell lymphoma; R/R CLL

MB-CART19.1

Phase I

Phase II

48

1 × 10^5/kg-3 × 10^6/kg

NR

NCT03881774

B-cell lymphoma

CAR-T cells

Phase I

20

(0.5–3) × 10^6/kg

NR

NCT04176913

DLBCL; FL; MCL; SLL

LUCAR-20S CAR-T cells

Phase I

41

NR

NR

NCT04156243

B-cell lymphoma

CD19 CAR T cells

Early phase I

20

NR

NR

NCT04089215

NHL; DLBCL; FL

CD19 CAR-T

Phase II

82

1.0 × 10^8 and 1.5 × 10^8 cells

Three month ORR: 60.3%

NCT04205838

DLBCL; High grade B-cell lymphoma; R/R tFL; R/R PMBCL

Axicabtagene Ciloleucel

Phase II

36

NR

NR

NCT04464200

DLBCL; PMBCL;

tFL; CLL; MZL; WM; Burkitt’s lymphoma; Primary CNS lymphoma

19(T2)28z1xx CAR T cells

Phase I

60

Planned flat-dose levels: (25, 50, 100, 150, 200) × 10^6 cells;

De-escalation dose: 12.5 × 10^6 cells.

NR

NCT04545762

Refractory NHL; Burkitt lymphoma; MCL; FL; PMBCL;

DLBCL; SLL

CD19 CAR-T cells

Phase I

36

Starting dose: 5 × 10^5 cells/kg

NR

NCT03999697

DLBCL; FL; MCL; Plasma cell neoplasm

CD22 CAR-T

Phase I

10

NR

NR

NCT04214886

B-ALL;

B-cell lymphoma

CD19-CD34 CAR-T

Phase I

24

1 × 10^6 cells/kg (± 20%) to 2 × 10^6 cells/kg

NR

NCT03666000

NHL; B-ALL

PBCAR0191

Phase I

Phase II

92

Starting dose: 3 × 10^5 cells/kg;

Subsequent dose groups: escalating doses to a maximum dose of 9 × 10^6 cells/kg.

NR

NCT02772198

B-ALL; B-NHL

CD19 CAR T cells

Phase I

Phase II

300

NR

ORR was 84% (30/36) in ALL and 62% (32/52) in NHL.

NCT04156178

B-cell lymphoma

CD20-CD19 CAR-T

Early phase I

12

NR

NR

NCT03743246

Precursor cell lymphoblastic leukemia- lymphoma; B-cell lymphoma

JCAR017

Phase I

Phase II

121

0.05 × 10^6–0.75 × 10^6 cells/kg

NR

NCT03676504

ALL; CLL; DLBCL; FL; MCL

CD19 CAR T Cells

Phase I

Phase II

48

1 × 10^6 cells/m^2 to 20 × 10^7 cells/m^2

NR

NCT03448393

ALL;

B-cell lymphoma; B-NHL

CD19/CD22 CAR T- Cells

Phase I

89

1 × 10^5 cells/kg (+/− 20%); 3 × 10^5 cells/kg (+/− 20%); 1 × 10^6 cells/kg; 3 × 10^6 cells/kg (+/− 20%); 1 × 10^7 cells/kg (+/− 20%).

NR

NCT04186520

B-NHL; MCL

CAR-T

Phase I

Phase II

32

2.5 × 10^6 cells/kg

NR

NCT02631044

NHL; DLBCL; FL; MCL; PMBCL

JCAR017

Phase I

314

50 × 10 CAR-T cells [one or two doses], 100 × 10 CAR-T cells, and 150 × 10 CAR-T cells.

ORR was 73% and CR rate was 53% among 256 patients with B-NHL.

NCT03744676

B-NHL;

B-cell lymphoma;

DLBCL

lisocabtagene maraleucel

Phase II

80

NR

NR

NCT02706405

DLBCL; PMBCL

JCAR014

Phase I

42

NR

NR

NCT04226989

ALL; NHL

CT-RD06

Early phase I

72

NR

NR

NCT04314843

B-cell lymphoma

Axicabtagene Ciloleucel

Phase I

Phase II

36

NR

NR

NCT03497533

B-NHL

TriCAR-T-CD19

Phase I

Phase II

6

(0.5–1) × 10^6 CAR-T cells/kg

NR

NCT03720496

B-NHL

CD19-TriCAR-T

Phase I

6

(0.1–1) × 10^6 cells/kg

NR

NCT03105336

FL; MZL; Indolent NHL

Axicabtagene ciloleucel

Phase II

160

NR

NR

NCT03310619

NHL; DLBCL; FL

JCAR017

Phase I

Phase II

75

50 × 10^6 CAR-T cells; 100 × 10^6 CAR-T cells.

NR